DoorDash, Inc. (NASDAQ:DASH – Free Report) – Research analysts at Cantor Fitzgerald lifted their FY2025 EPS estimates for shares of DoorDash in a report released on Wednesday, February 12th.

Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target The firm cited “significant” upside from the current valuation for the ...

The U.S. Senate voted on Tuesday by a 51-45 vote to confirm President Donald Trump's nominee Howard Lutnick, the billionaire ...

Cantor Fitzgerald analyst C. Duncan expects that the company will earn ($2.88) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $121.00 price objective on the stock.

Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals (PHAT) with an Overweight rating and $23 price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help you ...

Cantor Fitzgerald Equity Opportunity Fd earns a Low Process Pillar rating. The main driver of the rating is the fund's weak long-term risk-adjusted performance. This can be seen in its five-year ...

Cantor Fitzgerald High Income Fd earns an Average Process Pillar rating. The predominant contributor to the rating is the parent firm's five-year risk-adjusted success ratio of 81%. The measure ...

It was the last call he would ever make. Two floors down on the Cantor Fitzgerald floor, trader Jimmy DeBlase was on the phone to his wife, Marion, when a sound like thunder interrupted them.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...